Podcast Episodes

Back to Search
The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer
The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer

Episode 79

In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–tar…

4 years, 8 months ago

Short Long
View Episode
Managing Serious Adverse Events Associated with BTK Inhibitor Treatment
Managing Serious Adverse Events Associated with BTK Inhibitor Treatment

Episode 78

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy.…

4 years, 8 months ago

Short Long
View Episode
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 2: Patient Strategies for Self-Management
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 2: Patient Strategies for Self-Management

Episode 77

In this podcast episode, Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. T…

4 years, 8 months ago

Short Long
View Episode
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions

Episode 76

In this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. To…

4 years, 8 months ago

Short Long
View Episode
Adverse Events Associated with BTK Inhibitor Treatment
Adverse Events Associated with BTK Inhibitor Treatment

Episode 74

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics …

4 years, 8 months ago

Short Long
View Episode
BTK Inhibitors in CLL and Lymphomas: Overview and  Current Indications
BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications

Episode 75

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CL…

4 years, 8 months ago

Short Long
View Episode
Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Episode 72

In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the …

4 years, 8 months ago

Short Long
View Episode
Expert Answers to HCP Questions on CAR T-Cell Therapy
Expert Answers to HCP Questions on CAR T-Cell Therapy

Episode 73

In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current be…

4 years, 8 months ago

Short Long
View Episode
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies

Episode 71

In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clini…

4 years, 8 months ago

Short Long
View Episode
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide

Episode 70

In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venet…

4 years, 8 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us